Pedro Berraondo
Pamplona, NC, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 165 publications
Engineering interleukin-10 for therapeutic applications.
Journal: International review of cell and molecular biology
Published: May 20, 2026
Editorial: Current insights in melanoma immunology, immune escape and immunotherapy advances.
Journal: Frontiers in immunology
Published: April 29, 2026
Cross-priming underlies the efficacy of antibody-drug conjugates and immunotherapy combinations.
Journal: Trends in immunology
Published: April 15, 2026
Insights into ctDNA assessment to detect minimal residual disease (MRD) in localized colorectal cancer.
Journal: Scientific reports
Published: March 23, 2026
CD137 agonists in mice suppress germinal center responses by increasing the immunosuppressive activity of follicular regulatory T-cells.
Journal: The EMBO journal
Published: January 04, 2026
Antibody-Drug Conjugates Synergize with Agonist Anti-CD137 Monoclonal Antibodies in Solid Tumors.
Journal: Cancer research
Published: December 22, 2025
Trispecific engager overcomes tumoural immunosuppressive environment.
Journal: Nature biomedical engineering
Published: December 10, 2025
Monomethyl-auristatin E-based anti-CD137 (4-1BB) antibody drug conjugates are not suitable tools to deplete activated T lymphocytes.
Journal: Immunobiology
Published: October 27, 2025
TNFR1 expression on cancer cells mediates immune escape and an immunosuppressive microenvironment.
Journal: The Journal of experimental medicine
Published: October 08, 2025
Histone methyl-transferase G9a inhibition boosts the efficacy of immune checkpoint inhibitors in experimental hepatocellular carcinoma.
Journal: Cell reports. Medicine
Published: July 27, 2025
Dichotomy of IL-27 in tumor immunity.
Journal: International review of cell and molecular biology
Published: July 23, 2025
Last Updated: 09/26/2026